Press Release Archive

12.16.2013

Pfizer Declares First-Quarter 2014 Dividend

12.04.2013

Pfizer Expands Clinical Trial Data Access Policy And Launches Data Access Portal

12.02.2013

Pfizer Acquires Polocard, Poland’s Leading Over-The-Counter Heart Attack Prevention Brand

11.25.2013

Just in Time for Peak Travel Season, Introducing New Robitussin® DM Max Liquid-Filled Capsules

11.21.2013

Pfizer’s XALKORI® Granted Regular FDA Approval

11.21.2013

Pfizer And GSK To Initiate Study Of Novel Combination Therapy In Patients With Melanoma

11.18.2013

Pfizer Announces FDA Approval Of Supplemental Application To Expand XELJANZ® (tofacitinib citrate) Labeling To Include Additional Patient-Reported Outcomes Data For Adults With Moderately To Severely Active Rheumatoid Arthritis

11.14.2013

Pfizer Subsidiary, Wyeth LLC, To Redeem 5.500% Notes Due February 1, 2014

11.08.2013

Pfizer Announces Top-Line Results Of Phase 3B/4 Study Of RAPAMUNE® (sirolimus) In Renal Transplant Recipients

11.05.2013

Former U.S. President Jimmy Carter And Pfizer Celebrate 15-Year Effort To Help End Blinding Trachoma As A Public Health Concern

11.04.2013

Pfizer Receives FDA Approval For A Prior Approval Supplement For EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII

11.04.2013

JDRF Teams Up with Pfizer’s Centers for Therapeutic Innovation to Support Novel Translational Research in Type 1 Diabetes